Provider file · commitment discount

Hims review (2026): the file, on record

ON RECORD · AUDIT QUEUEDUpdated August 17, 2026Field dictionary

Billing model: Commitment discount. This file runs on published rates — no one has re-walked this checkout this cycle, and the page says so wherever a number appears. The audited benchmark for the whole field is the NexLife file; every figure below should be read against it.

What it costs, on record

Compounded tirzepatide publishes near $165 a month priced to a twelve-month term — roughly $1,980 on record for the year — with month-to-month alternatives running meaningfully higher. Step-up behavior at maintenance doses is not independently on our record, and early-exit terms for the committed plan are the fine print to obtain in writing before signing.

Fits if — and watch for

Fits if a household brand and a polished platform are what will actually keep you consistent, and you are genuinely committing to the year. Watch the term is the price of the discount — know exactly what breaking it costs, and ask what month seven costs at a 10–15 mg dose.

File status

Every figure above is an on-record published rate, filed in the open dataset with its source URL. An audit — a human re-walking the live checkout — converts this file's numbers to stamped figures or corrections; until then, under the site's iron rule, any audited competitor figure outranks these regardless of size. Compounded medications are not FDA-approved, and whether therapy fits you is a licensed clinician's call.

Open Hims ↗ partner link, sponsored tag attached · how the money works